Vratsa

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Lung cancer2 trials
• Chronic lymphocytic leukaemia1 trial
• COPD1 trial
• Metastatic breast cancer1 trial
• Sarcoma1 trial
• Schizophrenia1 trial

Phase

• Phase 35 trials
• Phase 21 trial

Status

• Active, not recruiting3 trials
• Completed2 trials
• Terminated1 trial

Lead sponsor

• AstraZeneca4 trials
• Acerta Pharma BV1 trial
• Otsuka Pharmaceutical Development & Commercialization, Inc.1 trial

Running trials

• Active, not recruiting

  A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

  NCT02970318· Phase 3· Acerta Pharma BV· Source

• Active, not recruiting

  Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

  NCT02542293· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

  NCT01933932· Phase 3· AstraZeneca· Source

Closed trials

• Completed

  An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.

  NCT05492877· Phase 2· AstraZeneca· Source

• Terminated

  A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia

  NCT04109950· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Completed

  Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

  NCT02000622· Phase 3· AstraZeneca· Source